FindTrial
Sign In

BMS-936558

BIOLOGICAL4 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, American University of Beirut Medical Center

Conditions

CholangiocarcinomaHematologic NeoplasmsMelanoma (Skin)Unresectable or Metastatic Melanoma

Phase 1

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
CompletedNCT01176461
H. Lee Moffitt Cancer Center and Research InstituteMelanoma (Skin)
Start: 2010-08-04End: 2016-12-12Updated: 2023-01-18
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
CompletedNCT02061761
Bristol-Myers SquibbHematologic Neoplasms
Start: 2014-03-13End: 2022-02-16Updated: 2023-03-24

Phase 2

A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma
TerminatedNCT04648319
American University of Beirut Medical CenterCholangiocarcinoma
Start: 2021-04-15End: 2022-01-17Updated: 2022-02-23

Phase 3

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
CompletedNCT01721746
Bristol-Myers SquibbUnresectable or Metastatic Melanoma
Start: 2012-12-21End: 2020-12-29Updated: 2022-04-19

Related Papers

Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022
Blood Advances2025-03-033 citations
Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
2023-08-075 citations
A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)
BMC Cancer2022-12-128 citations
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Regular and Young Investigator Award Abstracts2022-11-011 citations
Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy
Cancer Science & Research2021-12-30
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
JNCI Cancer Spectrum2020-12-0720 citations
Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma
Cancer Research2019-07-011 citations
Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma
Clinical Research (Excluding Clinical Trials)2019-07-011 citations
The Reality of Precision Medicine in Metastatic Melanoma
Oncology Times2018-03-13
Abstract 4891: A mass spectrometry-based serum test to predict outcome of treatment with nivolumab: Analysis of samples taken during therapy
Cancer Research2016-07-153 citations
Correlation between metastatic site and response to anti-<i>Programmed Death-1</i> (PD-1) agents in melanoma.
Journal of Clinical Oncology2016-05-2018 citations
Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).
Journal of Clinical Oncology2015-05-2015 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
2015-03-182011 citations
Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).
Journal of Clinical Oncology2014-05-2014 citations